ClinicalTrials.gg
TerminatedNCT03351231Updated Aug 26, 2020Results posted

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

A Phase 1/2 interventional study of BMS-986242 and Nivolumab in Cancer, sponsored by Bristol-Myers Squibb. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
Inability to meet protocol objectives

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate safety of experimental medication BMS-986242 and Nivolumab in patients with advanced cancers.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 7 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Histologic or cytological confirmation of a that is advanced ( and/or unresectable) with measureable disease per v1.1
  • Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting if such a therapy exists
  • (ECOG) performance status of 0-1
  • Ability to swallow tablets
  • Adequate bone marrow and organ function, as defined by the protocol

Exclusion criteria

Exclusion Criteria:

  • Participants with known or suspected , untreated CNS metastases, or with the CNS as the only site of disease (patients with controlled brain metastasis allowed to enroll)
  • Ocular melanoma
  • Any significant acute or chronic medical illness
  • Prior
  • Other active malignancy requiring concurrent intervention
  • Prior organ allograft or bone marrow transplantation
  • Participants with active, known, or suspected disease
  • Requirement for daily supplemental oxygen
  • Uncontrolled or significant cardiovascular disease
  • Pre-existing liver disease
  • Gastrointestinal disease known to interfere with absorption

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    BMS-986242 administered in combination with Nivolumab

    Drug: BMS-986242 · Biological: Nivolumab

  • Experimental
    Dose Expansion

    BMS-986242 administered in combination with Nivolumab

    Drug: BMS-986242 · Biological: Nivolumab

Interventions

  • DrugBMS-986242

    Specified dose on specified days

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: BMS-936558, Anti-PD-1

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AE)

    The primary objective to establish safety to be measured by the primary endpoint of AEs

    Time frame: From initiation of study treatment until 100 days after discontinuation of study treatment

  2. Number of Participants With Serious Adverse Events (SAE)

    The primary objective to establish safety to be measured by the primary endpoint of SAEs

    Time frame: From the date of participant's written consent until 100 days after discontinuation of nivolumab or participation in the study

  3. Number of Participants With Dose Limiting Toxicities (DLT)

    The primary objective to establish safety to be measured by the primary endpoint of dose limiting toxicities

    Time frame: Approximately 2 years

  4. Number of Participants With AEs Leading to Discontinuation

    The primary objective to establish safety to be measured by the primary endpoint of AEs leading to discontinuation

    Time frame: Approximately 2 years

  5. Number of Deaths

    The primary objective to establish safety to be measured by the primary endpoint of deaths

    Time frame: Approximately 2 years

  6. Number of Participants With Laboratory Abnormalities

    The primary objective to establish safety to be measured by the primary endpoint of clinical laboratory test abnormalities

    Time frame: Approximately 2 years

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  2. Time of Maximum Observed Plasma Concentration (Tmax)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  3. Area Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  4. Area Under the Concentration-time Curve From Time Zero to Infinity [AUC(INF)]

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  5. Trough Observed Plasma Concentration at the End of the Dosing Interval (Ctrough)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  6. Apparent Elimination Half-life (T-HALF)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  7. Apparent Total Body Clearance (CLT/F)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  8. Apparent Volume of Distribution at Steady State (Vss/F)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  9. Accumulation Index (AI)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0. Accumulation index, calculated based on ratio of area under the curve (AUC) and Cmax at steady state to after the first dose.

    Time frame: Approximately 2 years

  10. Percent Urinary Recovery Over 24 Hours (%UR24)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  11. Percent Urinary Recovery Over 72 Hours (%UR72)

    The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

    Time frame: Approximately 2 years

  12. Incidence of Anti-drug Antibody (ADA) to Nivolumab in Combination With BMS-986242

    Baseline ADA-positive participant is defined as a participant who has a ADA detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.

    Time frame: Approximately 2 years

  13. Overall Response Rate (ORR)

    ORR in participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors

    Time frame: Approximately 2 years

07

Results

Posted Oct 8, 2019

Participant flow

Combination Therapy Period
Participant flow — Combination Therapy Period
MilestoneBMS-986242 12.5 mg + Nivolumab 480 mg
Started5
Completed0
Not completed5
Withdrew: Administrative reason by the sponsor1
Withdrew: Disease progression2
Withdrew: Study drug toxicity1
Withdrew: Adverse event unrelated to study drug1
Safety Follow-Up Period
Participant flow — Safety Follow-Up Period
MilestoneBMS-986242 12.5 mg + Nivolumab 480 mg
Started3
Completed0
Not completed3
Withdrew: Participant withdrew consent1
Withdrew: Other reason2

Outcome measures

PrimaryNumber of Participants With Adverse Events (AE)

The primary objective to establish safety to be measured by the primary endpoint of AEs

Time frame:
From initiation of study treatment until 100 days after discontinuation of study treatment
Reported as:
Number · Number of participants
Number of Participants With Adverse Events (AE)
Number of participantsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of Participants With Adverse Events (AE)NA
PrimaryNumber of Participants With Serious Adverse Events (SAE)

The primary objective to establish safety to be measured by the primary endpoint of SAEs

Time frame:
From the date of participant's written consent until 100 days after discontinuation of nivolumab or participation in the study
Reported as:
Number · Number of participants
Number of Participants With Serious Adverse Events (SAE)
Number of participantsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of Participants With Serious Adverse Events (SAE)NA
PrimaryNumber of Participants With Dose Limiting Toxicities (DLT)

The primary objective to establish safety to be measured by the primary endpoint of dose limiting toxicities

Time frame:
Approximately 2 years
Reported as:
Number · Number of participants
Number of Participants With Dose Limiting Toxicities (DLT)
Number of participantsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of Participants With Dose Limiting Toxicities (DLT)NA
PrimaryNumber of Participants With AEs Leading to Discontinuation

The primary objective to establish safety to be measured by the primary endpoint of AEs leading to discontinuation

Time frame:
Approximately 2 years
Reported as:
Number · Number of participants
Number of Participants With AEs Leading to Discontinuation
Number of participantsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of Participants With AEs Leading to DiscontinuationNA
PrimaryNumber of Deaths

The primary objective to establish safety to be measured by the primary endpoint of deaths

Time frame:
Approximately 2 years
Reported as:
Number · Number of deaths
Number of Deaths
Number of deathsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of DeathsNA
PrimaryNumber of Participants With Laboratory Abnormalities

The primary objective to establish safety to be measured by the primary endpoint of clinical laboratory test abnormalities

Time frame:
Approximately 2 years
Reported as:
Number · Number of participants
Number of Participants With Laboratory Abnormalities
Number of participantsBMS-986242 12.5 mg + Nivolumab 480 mg
Number of Participants With Laboratory AbnormalitiesNA
SecondaryMaximum Observed Plasma Concentration (Cmax)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryTime of Maximum Observed Plasma Concentration (Tmax)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve in 1 Dosing Interval [AUC(TAU)]

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve From Time Zero to Infinity [AUC(INF)]

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryTrough Observed Plasma Concentration at the End of the Dosing Interval (Ctrough)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryApparent Elimination Half-life (T-HALF)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryApparent Total Body Clearance (CLT/F)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryApparent Volume of Distribution at Steady State (Vss/F)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryAccumulation Index (AI)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0. Accumulation index, calculated based on ratio of area under the curve (AUC) and Cmax at steady state to after the first dose.

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryPercent Urinary Recovery Over 24 Hours (%UR24)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryPercent Urinary Recovery Over 72 Hours (%UR72)

The Pharmacokinetic (PK) parameters are assessed for BMS-986242 and selected metabolites following single-dose administration in Cycle 00 and multiple-dose administration in Cycle 0

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryIncidence of Anti-drug Antibody (ADA) to Nivolumab in Combination With BMS-986242

Baseline ADA-positive participant is defined as a participant who has a ADA detected sample at baseline. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment.

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR)

ORR in participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for solid tumors

Time frame:
Approximately 2 years

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events (AEs) are monitored from initiation of study treatment (monitored from participant's written consent for Serious Adverse Events) up through 100 days post-End of Treatment (EOT); Study Start of December 2017 and Study End of August 2018 (assessed approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BMS-986242 12.5 mg + Nivolumab 480 mg0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

All treated participants; Note: study terminated following starting dose of BMS-986242 12.5 mg; dosing did not escalate.

Age, Categorical
Age, Categorical(Participants)BMS-986242 12.5 mg + Nivolumab 480 mg
<=18 years0
Between 18 and 65 years2
>=65 years3
Age, Continuous
Age, Continuous(Years)BMS-986242 12.5 mg + Nivolumab 480 mg
Mean67.8 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)BMS-986242 12.5 mg + Nivolumab 480 mg
Female1
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BMS-986242 12.5 mg + Nivolumab 480 mg
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BMS-986242 12.5 mg + Nivolumab 480 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White4
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294-3300, United States
  • Hoag Memorial Hospital Presbyterian
    Los Angeles, California 90033, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Local Institution
    Baltimore, Maryland 21287, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Aug 2018, 9 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 22, 2017
StartActual
Nov 27, 2017
Primary completionActual
Aug 28, 2018
CompletionActual
Aug 28, 2018
Results first posted
Oct 8, 2019
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03351231
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
Nov 27, 2017
Primary completion
Aug 28, 2018
Completion
Aug 28, 2018
Results posted
Oct 8, 2019
Last update
Aug 26, 2020

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion